AIRC 2021 - Reverse the silencing: Targeting the MEF2-class IIa HDACs axis in leiomyosarcomas. AIRC 2021 - Reverse the silencing: Targeting the MEF2-class IIa HDACs axis in leiomyosarcomas.

Finanziato da Fondazione AIRC

AIRC 2020 - A druggable approach to modulate cancer epigenetics AIRC 2020 - A druggable approach to modulate cancer epigenetics

Finanziato da Fondazione AIRC

AIRC 2022 - Deciphering the molecular mechanisms driving the interplay between tumor-associated immune cells and cancer cells AIRC 2022 - Deciphering the molecular mechanisms driving the interplay between tumor-associated immune cells and cancer cells

Finanziato dalla Fondazione AIRC, Ministero della Salute